BeiGene, Ltd. - American Depositary Shares (BGNE)
BGNE moved a median of +0.11% 30 minutes after news, and +0.06% by the close. How BGNE actually reacts to news — the realized, point-in-time move the market made, measured across 191 labeled events over the last three years with zero look-ahead.
BGNE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 43% | 187 |
| 30-min | +0.11% | 52% | 187 |
| 60-min | -0.00% | 50% | 187 |
| to close | +0.06% | 51% | 187 |
| Middle 50% of BGNE reactions | -0.72% to +0.68% |
|---|---|
| Median reaction (30-min) | +0.11% |
| Measured reactions | 191 |
Half of all BeiGene, Ltd. - American Depositary Shares news events land between -0.72% and +0.68% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when BGNE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BGNE's baseline. Nothing else.
Recent BGNE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer | Press release | Business Wire | — | — | |
| Form 10-K/A BeiGene, Ltd. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | — | |
| TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy | Press release | Business Wire | +0.09% | +0.04% | |
| BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference | Press release | Business Wire | +0.01% | -0.52% | |
| Form 8-K BeiGene, Ltd. For: Dec 23 | SEC filing · Form 8-K | SEC EDGAR | +0.01% | -0.52% | |
| BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor | Press release | Business Wire | +0.95% | +1.24% | |
| Form 8-K BeiGene, Ltd. For: Dec 09 | SEC filing · Form 8-K | SEC EDGAR | +0.59% | -4.10% | |
| BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets | Press release | Business Wire | +0.59% | -4.10% | |
| BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL | Press release | Business Wire | +2.45% | -1.19% | |
| BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024 | Press release | Business Wire | -0.05% | -4.25% | |
| European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer | Press release | Business Wire | +2.28% | +2.41% | |
| BeiGene to Present at Upcoming Investor Conferences | Press release | Business Wire | -1.05% | +1.00% | |
| BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA | Press release | Business Wire | +0.68% | -0.25% | |
| Form 8-K BeiGene, Ltd. For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | +0.68% | -0.25% | |
| BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer | Press release | Business Wire | -0.32% | -0.15% | |
| Form 8-K BeiGene, Ltd. For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | -0.32% | -0.15% | |
| BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates | Press release | Business Wire | -1.51% | -2.20% | |
| Form 10-Q BeiGene, Ltd. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.06% | -0.66% | |
| Form 8-K BeiGene, Ltd. For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +1.04% | -0.68% | |
| BeiGene to Present at the Jefferies London Healthcare Conference | Press release | Business Wire | -2.17% | -2.55% | |
| BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024 | Press release | Business Wire | -0.22% | -0.05% | |
| BeiGene Mourns Death of Beloved Board Member Donald Glazer | Press release | Business Wire | -0.08% | +0.98% | |
| Form 8-K BeiGene, Ltd. For: Oct 25 | SEC filing · Form 8-K | SEC EDGAR | -0.08% | +0.98% | |
| BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma | Press release | Business Wire | +0.22% | -0.04% | |
| BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024 | Press release | Business Wire | -0.34% | -0.94% | |
| Form 8-K BeiGene, Ltd. For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | -1.00% | -5.31% | |
| BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers | Press release | Business Wire | -0.04% | -0.21% | |
| Form 8-K BeiGene, Ltd. For: Sep 25 | SEC filing · Form 8-K | SEC EDGAR | -0.08% | +0.25% | |
| Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors | Press release | Business Wire | -0.08% | +0.25% | |
| BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy | Press release | Business Wire | -0.36% | -0.77% | |
| BeiGene Singapore Raises Awareness for World Lymphoma Awareness Day 2024: It's Time for Honest Talk | Press release | PR Newswire | -1.07% | -0.76% | |
| BeiGene Announces Updates to Commercial Leadership Team | Press release | Business Wire | +0.45% | +1.92% | |
| BeiGene Highlights TEVIMBRA® Data in Lung and Gastrointestinal Cancers at ESMO 2024 | Press release | Business Wire | +0.45% | +1.92% | |
| Form 8-K BeiGene, Ltd. For: Aug 29 | SEC filing · Form 8-K | SEC EDGAR | -0.43% | +0.33% | |
| BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference | Press release | Business Wire | +0.09% | -1.37% | |
| BeiGene’s BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL | Press release | Business Wire | -0.33% | -0.21% | |
| BeiGene Enters Next Phase of Global Growth with Announcement of Second Quarter 2024 Financial Results and Corporate Updates | Press release | Business Wire | -2.07% | -1.82% | |
| Form 10-Q BeiGene, Ltd. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.07% | -1.82% | |
| Form 8-K BeiGene, Ltd. For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -2.07% | -1.82% | |
| Form S-4 BeiGene, Ltd. | SEC filing · Form S-4 | SEC EDGAR | -2.07% | -1.82% | |
| BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World | Press release | Business Wire | -0.41% | +1.63% | |
| BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer | Press release | Business Wire | +0.54% | +0.86% | |
| Form 8-K BeiGene, Ltd. For: Jul 17 | SEC filing · Form 8-K | SEC EDGAR | +0.54% | +0.86% | |
| BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024 | Press release | Business Wire | +0.00% | -0.79% | |
| BeiGene and NewBridge Pharmaceuticals FZ LLC Mutually Agree to Conclude BRUKINSA® (Zanubrutinib) Partnership in the Middle East and Africa (MENA) Region | Press release | Business Wire | +0.00% | -0.79% | |
| Form 8-K BeiGene, Ltd. For: Jun 05 | SEC filing · Form 8-K | SEC EDGAR | +0.45% | -0.13% | |
| Form S-8 BeiGene, Ltd. | SEC filing · Form S-8 | SEC EDGAR | +0.45% | -0.13% | |
| BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference | Press release | Business Wire | -0.44% | +4.09% | |
| BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL | Press release | Business Wire | -0.34% | -1.08% | |
| BeiGene Highlights New Hematology Portfolio and Pipeline Data at EHA2024 | Press release | Business Wire | +0.05% | +1.44% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BGNE section they belong to.
Where else BGNE is measured.
BGNE earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| TAKEDA PHARMA (TKPYY) | 192 | 0.00% | 47% |
| Arbutus Biopharma Corporation (ABUS) | 191 | +0.11% | 52% |
| CYTODYN INC (CYDY) | 191 | -0.07% | 45% |
| BAVARIAN NORDIC R/I S/ADR (BVNRY) | 190 | 0.00% | 29% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is BeiGene, Ltd. - American Depositary Shares's median reaction calculated?
Every labeled BGNE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 191 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 52% of BGNE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BGNE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.